Differential effects of imeglimin and metformin on insulin and incretin secretion—An exploratory randomized controlled trial

Abstract

Unlike metformin, imeglimin enhances GIP secretion as well as GLP-1 secretion, in addition to its direct insulinotropic mechanism of glucose control, emphasizing its potential as a therapeutic option in the treatment of patients with diabetes.